BACKGROUND The optimum duration of dual antiplatelet therapy (DAPT) after drug eluting stent (DES) implantation in patients with or without acute coronary syndromes (ACS) is unknown. We aim to evaluate the efficacy and safety of long duration DAPT (L-DAPT) compared to short duration DAPT (S-DAPT) after drug-eluting stent (DES) implantation in patients who presented with or without ACS.
RESULTS
We identified 3 RCTs (DAPT, ITALIC, RESET) in which 15,587 patients were randomized to S-DAPT versus L-DAPT (4,969 ACS and 10,618 non-ACS). Clinical outcomes with S-DAPT compared with L-DAPT in ACS and non-ACS are summarized in table. BACKGROUND It has been proven that presence of chronic total occlusion (CTO) in other than infarct-related artery (IRA) in patients with NSTEMI is associated with higher rates of in-hospital and longterm mortality than in patients without CTO. However, there is a lack of data regarding the influence of the number of untreated CTOs on early and long-term prognosis in NSTEMI population. Therefore the aim of the study was to comprehensively evaluate the effect of the number of CTOs on 12-month major adverse cardiac events (MACE) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease (MV CAD) treated with percutaneous coronary intervention (PCI).
METHODS The consecutive data of 1242 patients with NSTEMI admitted to the Clinic between 2006 and 2012 were analyzed. Only patients with CTO and MV CAD treated with PCI were included for further analysis. The differentiation between CTO and acute occlusion was determined by the compilation of the occlusion morphology, electrocardiographic recording and a possible history of previously documented acute coronary events in the same artery. Patients with a history or qualified to coronary artery bypass grafting during hospitalization were excluded from further analysis. 545 patients met all study criteria and were divided according to the number of CTOs in coronary angiography: CTO¼0 (n¼314)without CTO, CTO¼1 (n¼179)with only one documented CTO and CTO!2 (n¼52)-with more than one CTO. CONCLUSIONS In patients with NSTEMI and MV CAD treated with PCI greater number of CTO localized in non-IRA was associated with higher incidence of 12-month MACE and was an independent factor affecting 12 month mortality. 
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